Press Releases

Oct 29, 2024

MilliporeSigma today announced a $76 million expansion of its ADC manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri.

Oct 09, 2024

MilliporeSigma has opened its new €290 million biosafety testing facility in Rockville, Maryland, USA.

Sep 10, 2024

MilliporeSigma launched the first single-use reactor specifically designed to manufacture antibody drug conjugates (ADCs).

Sep 09, 2024

MilliporeSigma has partnered with the Emmy^® and Golden Globe^® Award-winning ABC series "Abbott Elementary" to raise awareness around STEM education.

Sep 03, 2024

MilliporeSigma today announced that the company’s Life Science business achieved EXCiPACT cGMP certification for PAMs at its major global CCM production sites.

Aug 01, 2024

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced that the company’s Life Science business has closed the transaction to acquire Mirus Bio.

Jul 24, 2024

MilliporeSigma announced that its Life Science business sector has signed a non-binding MoU with Gene Therapy Research Institution Co., Ltd. (GTRI).

Jul 03, 2024

MilliporeSigma announced that the company’s Life Science business entered into a non-binding Memorandum of Understanding (MoU) with Afrigen Biologics to support the development of an mRNA vaccine technology platform.

Jun 18, 2024

SMC^® immunoassay technology from MilliporeSigma provides new understanding of cell dysfunction to slow disease progression

Jun 11, 2024

Facility to provide production-related quality control services for Life Science business and brings together 135 employees and various functions into one ~10,000 m2 building.

Jun 06, 2024

Expands facility by 25,000 square meters, nearly doubling size, adds new down filling capabilities and distribution space for Life Science customers, employs more than 470 people, including engineers, manufacturing, and distribution experts

Jun 04, 2024

MilliporeSigma announced today that Siren Biotechnology has been selected as the North American winner of its 13th Advance Biotech Grant Program.

May 29, 2024

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt Germany, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with KAIST.

May 28, 2024

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched its M-Trace^® Software & Mobile App, a comprehensive data tracking solution to digitize sterility testing.

May 22, 2024

MilliporeSigma today announced the signing of a definitive agreement to acquire Mirus Bio for US$ 600 million.

Apr 17, 2024

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, officially kicked off its global 2024 Curiosity Cube tour today in Darmstadt, Germany.

Apr 16, 2024

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the first all-in-one, validated genetic stability assay of its kind.

Mar 20, 2024

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, invests more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea.

Jan 24, 2024

MilliporeSigma announced that the Life Science business sector entered into a non-binding MoU with Mycenax Biotech to explore cooperation to bring innovative and high-capacity bioprocessing solutions to Taiwan and other international markets.

Dec 05, 2023

Combines generative AI, machine learning and computer-aided drug-design to increase the success rate of new drugs and therapies

Nov 21, 2023

Further develops its biosafety testing laboratories to meet local demand; new labs complete 2nd phase of company’s € 29 million Biologics Testing Center opened in 2022.

Nov 14, 2023

Accelerates digitalization in labs and manufacturing by offering traceable digital records of physical reference materials.

Sep 26, 2023

MilliporeSigma is the first CTDMO to offer integrated services for all critical stages of mRNA development, manufacturing, and commercialization, including products and testing.

Jul 12, 2023

Lenexa, Kansas, facility becomes company’s largest dry powder cell culture media facility and Center of Excellence

Jun 06, 2023

MilliporeSigma announced that Proteologix US Inc. (“Proteologix”) has been selected as the North American winner of its 12th Advance Biotech Grant program.

May 31, 2023

According to a recent study sponsored by the Life Science business of Merck KGaA, Darmstadt, Germany, mRNA technology is a “game-changer” for Asia-Pacific (APAC) vaccine manufacturers. Nearly 40 manufacturers participated in the survey.

May 31, 2023

Responds to global demand for biosafety testing for drug development and commercialization. Expansion creates nearly 500 new jobs in Glasgow and Stirling. Company’s investment to boost global testing capacity now tops € 350 million since mid-2022.

May 02, 2023

MilliporeSigma partners with MOTIE and Daejeon City for a new Asia-Pacific BioProcessing Center to advance life science.

Apr 26, 2023

Over 250 events expected to reach more than 45,000 future scientists on two continents. Hands-on experiments to focus on the impact of contamination on the planet and everyday life.

Apr 24, 2023

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the launch of its Ultimus® Single-Use Process Container Film.

Mar 27, 2023

Partnership to support Beyond Benign’s online learning platform and higher education program

Dec 07, 2022

Non-binding MoU signed between MilliporeSigma and Synplogen for collaborative initiatives.

Dec 06, 2022

MilliporeSigma a leading science and technology company, has acquired Massachusetts-based Erbi Biosystems.

Nov 16, 2022

MilliporeSigma today announced that its Life Science business sector is investing more than $ 286 million in its biosafety testing capacity at the company’s site in Rockville, Maryland.

Nov 07, 2022

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration with Biotheus.

Oct 04, 2022

The Life Science business of Merck KGaA, Darmstadt, Germany, has opened a commercial facility for its new Millipore^® CTDMO Services offering at the company’s site in Martillac, France.

Sep 21, 2022

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the opening of a viral clearance (VC) laboratory as part of the first building phase of its new € 29 million China Biologics Testing Center.

Sep 08, 2022

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that the Life Science business strengthened its manufacturing capabilities for single-use assemblies.

Aug 08, 2022

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched the VirusExpress^® 293 Adeno-Associated Virus (AAV) Production Platform.

Jul 19, 2022

7,000 solar panels produce energy to power 700 homes, Part of We Energies’ “Solar Now” program, bringing more renewable energy to Wisconsin, Reinforces company’s long-term commitment to renewable energy.

Jul 18, 2022

New facility to manufacture the company’s Hi-Flow™ Plus lateral flow membrane used in rapid diagnostic test kit manufacturing, including Covid-19

Jun 29, 2022

MilliporeSigma signed a non-binding Memorandum of Understanding (MoU) with the new biologics business of Lotte Group, outlining a planned collaboration to establish Lotte’s biologics manufacturing capabilities in the USA.

Jun 21, 2022

MilliporeSigma doubles high-potent active pharmaceutical ingredients (HPAPI) production capacity at Verona, Wisconsin facility.

Jun 14, 2022

The Life Science business of Merck KGaA, Darmstadt, Germany, collaborates with Agilent Technologies to advance Process Analytical Technologies (PAT).

May 23, 2022

The investment, which is the largest in a single site ever for the Life Science business sector, significantly increases membrane manufacturing capacities and enables the construction of a new filtration manufacturing facility.

May 18, 2022

MilliporeSigma today announced that the Life Science business further enhanced its commitment to Science, Technology, Engineering and Math (STEM) education, with the launch of its 2022 Curiosity Cube^® mobile science lab in Europe and North America.

Apr 28, 2022

MilliporeSigma’s First Asia Pacific Mobius^® Single-Use Manufacturing Center in Wuxi, China

Apr 21, 2022

ReadyStream^® system offers automated media preparation to conveniently provide a large volume of preheated media, eliminates five time-consuming steps.

Apr 14, 2022

ZooMAb^® antibodies first-ever antibody to be recognized for low-environmental impact by My Green Lab

Apr 05, 2022

MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies.

Feb 22, 2022

MilliporeSigma, the U.S. and Canada Life Science business sector of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash. The business combination is expected to enable the Life Science business to provide its customers with comprehensive end-to-end contract development and manufacturing organization (CDMO) services across the mRNA value chain. The Life Science business plans to further invest over € 500 million to scale up Exelead’s technology over the next ten years.

Feb 15, 2022

MilliporeSigma has entered into a collaboration with Waters Corporation to build and expand an Extractables and Leachables (E&L) Reference Library to include ion mobility measurements

Feb 07, 2022

MilliporeSigma today announced several organizational changes and a new operating model to support the long-term growth strategy of the Life Science business sector and to better serve the evolving needs of its global customers.

Jan 26, 2022

MilliporeSigma, a leading science and technology company, today announced that the Life Science business sector signed a non-binding Memorandum of Understanding (MoU) with ID Pharma, the advanced medical business within I’rom Group, outlining its planned support of the development and manufacturing of leading-edge gene therapy.

Jan 20, 2022

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that Elevian has been selected as the North American winner of its 2021 Advance Biotech Grant Program

Jan 11, 2022

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt Germany, a leading science and technology company, today announced the expansion of its Stable Isotope Center of Excellence in Miamisburg, Ohio.

Jan 06, 2022

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the signing of a definitive agreement to acquire Exelead.

Dec 29, 2021

MilliporeSigma today announced that it has been awarded a $136.7M USD contract award for the construction of a lateral flow membrane production facility over a three-year period at the company’s Sheboygan, Wisconsin site.

Dec 13, 2021

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the Life Science business sector has signed an agreement with biotechnology company Innovative Biotech.

Dec 13, 2021

MoU marks steps towards the first industry-academia collaboration for quantum biophysics medicines in South Korea

Dec 11, 2021

Award recognizes early in career scientists for Indonesia-based research

Nov 11, 2021

MilliporeSigma announced that the Life Science business sector signed a Memorandum of Understanding with local bio-venture company GI Innovation.

Nov 09, 2021

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the retirement of Jean-Phillipe Maurer as Head of Molsheim Operations, effective December 1.

Nov 03, 2021

MilliporeSigma today announced that the Life Science business sector will support SaudiVax Ltd. to design a manufacturing facility to localize manufacturing of biologics and vaccines for the MENA region.

Oct 28, 2021

MilliporeSigma today announced that its Life Science business sector has launched new technology and expanded capacity to advance ADC therapies.

Oct 21, 2021

Korea M Lab™ Collaboration Center marks five years of continuous operation, recording over 540 collaborations and trainings, benefitting over 1,000 biopharmaceutical and biotech customers

Oct 20, 2021

MilliporeSigma today announced that the Life Science business sector entered into a collaboration with Bio-valley (Beijing) Technology Co., LTD (Bio-valley) to establish technical talent training programs for China’s biopharmaceutical industry.

Oct 12, 2021

MilliporeSigma today announced the opening of its second Carlsbad, California-based facility, significantly expanding its CDMO footprint.

Oct 06, 2021

MilliporeSigma, the U.S. and Canadian life science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, was selected as a Manufacturer of the Year for its Danvers facility at the 6th Annual Manufacturing Awards Ceremony.

Oct 05, 2021

MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, announces that its Life Science business sector has signed an agreement licensing its patented CRISPR-Cas9 technology to California-based Cellecta, Inc.

Aug 27, 2021

MilliporeSigma today announced a donation of INR 1.7crore (194,000€) over two years to the Indian Institute of Technology (IIT), Bombay to support the development of clinical tests for Covid-19 disease severity assessment.

Jul 05, 2021

Lab marks five years of continuous operation and 400+ activities, benefitting more than 10,000 customers.

Jun 23, 2021

MilliporeSigma today announced that the Japanese Patent Office has issued a formal notice allowing the company’s patent application for its proxy-CRISPR technology.

Jun 09, 2021

MilliporeSigma will hold a collaborative seminar with the Korea Federation of Women’s Science and Technology Associations (KOFWST) about ways to ensure a safe and healthy laboratory environment for pregnant scientists.

May 26, 2021

To meet the high demand for lipids, a key component of mRNA-based vaccines and therapeutics, MilliporeSigma has launched a new, high-purity synthetic cholesterol product, nine months ahead of schedule.

May 20, 2021

MilliporeSigma today introduced a new solution improving productivity in the lab through a more flexible and streamlined nucleic acid purification process — GenElute™-E Single Spin purification kits.

May 18, 2021

MilliporeSigma today announced that VectorY has been selected as the European winner of its 2021 Advance Biotech Grant Program.

May 04, 2021

MilliporeSigma today announced a partnership with Topco Scientific Co. (TSC), a leading semiconductor supplier in Taiwan, to increase the use of more sustainable materials for the electronics industry.

Mar 30, 2021

MilliporeSigma today announced a strategic partnership with the Universitas Indonesia (FMIPA-UI) to establish the first Collaboration Laboratory between the company and the university.

Mar 17, 2021

MilliporeSigma will add a single-use assembly production unit at its Life Science Center in Molsheim, France.

Mar 15, 2021

As part of its ongoing commitment to renewable energy, MilliporeSigma has signed a 12-year, off-site, virtual power purchase agreement with Enel Green Power for the construction of a future wind and storage project in Texas.

Feb 15, 2021

MilliporeSigma has launched an enhanced Design for Sustainability (DfS) framework, a unique approach to holistically integrate sustainability into products, systems and services.

Feb 04, 2021

Building on its commitment to accelerate scientific research and science education, MilliporeSigma has announced seven expanded partnerships with leading nonprofit organizations across the world.

Jan 07, 2021

MilliporeSigma today announced the acquisition of AmpTec, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO).

Dec 07, 2020

MilliporeSigma today announced the broadening of its manufacturing footprint with a combined $47 million investment at its production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire.

Nov 20, 2020

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that its Massachusetts-based businesses, MilliporeSigma, EMD Serono, and EMD Performance Materials, have again been named to The Boston Globe’s annual “Top Places to

Nov 10, 2020

MilliporeSigma today announced that its first-to-market Blazar™ platform from the BioReliance^® portfolio has won R&D 100 and CPhI Awards for its ability to reduce testing times by up to 80 percent.

Nov 07, 2020

MilliporeSigma and Transcenta, a global biotherapeutics company, have announced a strategic technology collaboration to implement continuous manufacturing for protein therapeutics.

Nov 06, 2020

MilliporeSigma today announced the signing of a Letter of Intent with Donghao Lansheng (Group) Co., Ltd.

Oct 18, 2020

MilliporeSigma today announced that Combined Therapeutics Inc., Cambridge, Massachusetts, has been selected as the North American winner of its 2020 Advance Biotech Grant Program.

Oct 12, 2020

MilliporeSigma has bolstered its viral vector manufacturing capabilities with the launch of its VirusExpress™ Lentiviral Production Platform.

Oct 11, 2020

MilliporeSigma today announced that it has signed agreements licensing its CRISPR technology to two companies — PanCELLa, a cell therapy firm based in Toronto, Canada, and Takara Bio USA, Inc., a biotechnology company based in Mountain View, California.

Oct 07, 2020

MilliporeSigma is collaborating with D1Med, a Shanghai-based biopharmaceutical start-up precision-medical company, to accelerate production of D1Med’s 3D cell culture technology applications used in the drug discovery process.

Oct 07, 2020

MilliporeSigma today celebrated the topping-out ceremony for its new membrane production plant in Darmstadt, Germany.

Oct 05, 2020

MilliporeSigma today inaugurated a new $14.4 million industrial water treatment plant at its Jaffrey, New Hampshire, location.

Sep 08, 2020

MilliporeSigma today announced a $65 million expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin.

Sep 02, 2020

MilliporeSigma today announced the donation of research instruments and materials worth IDR 1.2 billion (€ 74,000) to support the efforts of Eijkman Institute for Molecular Biology, Indonesia

Jul 29, 2020

MilliporeSigma today announced that it won a Top Project of the Year award from Environment + Energy Leader for the company’s DOZN™ system.

Jul 14, 2020

MilliporeSigma has announced plans to build a new, $20 million laboratory facility in Buchs, Switzerland to support its rapidly growing reference materials business.

Jul 09, 2020

MilliporeSigma today opened its M Lab™ Collaboration Center in Shanghai, the company’s largest of nine centers worldwide.

Jul 05, 2020

MilliporeSigma today announced that VAR2 Pharmaceuticals has been selected as the European winner of its 2020 Advance Biotech Grant Program.

Jun 30, 2020

A new report details potential paths to solutions to overcoming the global Covid-19 crisis and ways to prepare for or even prevent a future pandemic.

Jun 30, 2020

MilliporeSigma today enhanced its advanced bioprocess portfolio through the acquisition of RESOLUTION Spectra Systems, a Meylan, France-based leader in bioprocess analytical monitoring.

Jun 09, 2020

MilliporeSigma and 10x Genomics, Inc., a single cell and spatial genomics technologies company, today announced that they have developed a powerful new option for biological experiments.

May 26, 2020

MilliporeSigma and Baylor College of Medicine today announced an extension of their ongoing collaboration to advance a manufacturing platform to fight Covid-19, accelerating the transition to Phase 1 clinical trials.

May 11, 2020

MilliporeSigma today announced that two of its CRISPR-Cas9-assisted genome-editing patents have been allowed in the United States.

Apr 30, 2020

MilliporeSigma today unveiled the next component of its BioContinuum™ Platform, the Bio4C™ Software Suite, creating a first-of-its-kind ecosystem that combines process control, analytics and plant-level automation.

Apr 21, 2020

MilliporeSigma today announced a second Carlsbad, California-based facility for its BioReliance® viral and gene therapy service offering.

Apr 13, 2020

MilliporeSigma and The Jenner Institute today announced that The Jenner Institute has laid the foundation for large-scale production of its Covid-19 vaccine candidate, ChAdOx1 nCoV-19.

Apr 06, 2020

MilliporeSigma today announced that the United States Patent and Trademark Office has granted the company’s patent for CRISPR-chrom technology.

Mar 03, 2020

MilliporeSigma today launched its LANEXO^® Lab Inventory, Safety and Compliance Management System, a new digital laboratory informatics solution designed to drastically reduce time in labs and improve data quality and traceability.

Mar 02, 2020

MilliporeSigma today launched its LANEXO™ Lab Inventory, Safety and Compliance Management System, a new digital laboratory informatics solution designed to drastically reduce time in labs and improve data quality and traceability.

Feb 17, 2020

MilliporeSigma today announced that it has been selected by Swedish molecular diagnostics firm Elypta as the contract manufacturer for Elypta’s clinical diagnostic liquid biopsy kits.

Feb 10, 2020

MilliporeSigma today introduced its BrightLab™ cloud-based inventory management and instrument connectivity platform for research scientists.

Jan 09, 2020

MilliporeSigma today announced the opening of new, non-profit center where Indian students and researchers can learn the latest genome-editing and single-molecule biomolecule biomarker detection technologies from MilliporeSigma experts.

Dec 18, 2019

MilliporeSigma today announced that it has signed a license agreement providing Promega Corp., a global life science manufacturer based in Madison, Wisconsin, access to MilliporeSigma’s foundational CRISPR intellectual property.

Nov 25, 2019

MilliporeSigma today announced that the Japan Patent Office and the Intellectual Property Office of Singapore have each allowed its patent application for the use of paired CRISPR nickases, bringing MilliporeSigma’s number of patents to 22 worldwide.

Nov 17, 2019

MilliporeSigma today announced the completion of a £9 million expansion to its Gillingham distribution center.

Nov 17, 2019

MilliporeSigma today announced it has received a prestigious R&D 100 Award for its Eshmuno® CP-FT Resin, a first-to-market product used in biopharmaceutical manufacturing.

Nov 11, 2019

MilliporeSigma today announced that it has signed a license agreement providing Evotec SE access to MilliporeSigma’s foundational CRISPR intellectual property.

Oct 18, 2019

MilliporeSigma today announced it has acquired FloDesign Sonics, of Wilbraham, Massachusetts, developer of a unique acoustic cell processing platform for the industrialization of cell and gene therapy manufacturing.

Sep 18, 2019

MilliporeSigma has launched its official flagship store on Alibaba’s 1688.com.

Sep 18, 2019

MilliporeSigma today announced an expansion of its Singapore biosafety testing laboratory services.

Aug 05, 2019

MilliporeSigma has acquired BSSN Software, a Darmstadt, Germany-based laboratory informatics company that makes data more readily accessible for ease of integration, collaboration, analysis and lon

Jul 23, 2019

MilliporeSigma today announced the signing of a non-binding Memorandum of Understanding (MoU) with Phanes Therapeutics, Inc. (Phanes) for a collaboration on the development and manufacture of biologics for the treatment of solid tumors.

Jul 17, 2019

MilliporeSigma and the Broad Institute of MIT and Harvard today announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for use in commercial research and product development.

Jun 19, 2019

MilliporeSigma today announced a national campus tour in China for the company’s first mobile protein research laboratory.

Jun 19, 2019

Merck KGaA, Darmstadt, Germany, today announced that its Massachusetts-based business sectors, MilliporeSigma, EMD Serono and EMD Performance Materials, have been named to the Boston Business Journal’s annual “Best Places to Work".

May 29, 2019

MilliporeSigma today announced the winners of its Advance Biotech Grant program in North America during its Biotech Start-up Summit at the Cambridge Innovation Center.

May 28, 2019

MilliporeSigma today announced that students from St Aloysius’ College in Carrigtwohill have won the company’s 2019 School Science Competition, now in its 15th year.

May 26, 2019

MilliporeSigma today announced the completion of a £2.7 million expansion to its Irvine biopharmaceutical production facility.

May 21, 2019

Merck KGaA, Darmstadt, Germany, today hosted a panel discussion on the occasion of the 72nd World Health Assembly in Geneva, Switzerland.

May 19, 2019

MilliporeSigma today announced its participation in a collaboration with the Vaccine Formulation Institute and the European Vaccine Initiative.

May 06, 2019

MilliporeSigma today announced that MDL, a team from Beijing University, has won the company’s first Retrosynthetic Reaction Prediction Contest.

Apr 29, 2019

MilliporeSigma today announced the handover of a fully equipped microbiological testing laboratory to the Food Safety and Standards Authority of India (FSSAI).

Apr 23, 2019

MilliporeSigma today launched Cyrene™ — a sustainable dipolar aprotic solvent, produced in two steps from a renewable cellulose source.

Apr 03, 2019

MilliporeSigma today announced that it has won an INTERPHEX Exhibitor Award for a new innovation in advancing next- generation bioprocessing.

Apr 01, 2019

MilliporeSigma today unveiled its BioContinuum™ Buffer Delivery Platform, a new building block in the BioContinuum™ Platform for next-generation bioprocessing, at INTERPHEX in New York City.

Mar 19, 2019

MilliporeSigma today officially opened its new M Lab™ Collaboration Center in Molsheim, France.

Mar 18, 2019

MilliporeSigma today announced the signing of a non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing.

Mar 17, 2019

MilliporeSigma today announced a new cloud-based, remote lab water service and monitoring capability available on all Milli-Q^® CLX 7000 clinical water purification systems.

Mar 13, 2019

MilliporeSigma today announced a CRISPR core partnership with Zhejiang University in Hangzhou, China.

Mar 07, 2019

MilliporeSigma is igniting student interest in science with its third annual Curiosity Cube^® mobile science lab tour.

Mar 04, 2019

MilliporeSigma today announced that the Canadian Patent Office has allowed MilliporeSigma’s patent application directed to the use of paired CRISPR nickases in eukaryotic cells.

Feb 18, 2019

MilliporeSigma today announced that the U.S. Patent and Trademark Office has issued a formal notice allowing MilliporeSigma’s patent application directed to its proxy-CRISPR technology.

Feb 03, 2019

MilliporeSigma today announced the winners of its Advance Biotech Grant program in Europe. The grant is given to small- and mid-size biotechnology companies that need funding and expertise to get their therapies to market.

Jan 14, 2019

MilliporeSigma today announced that it has been recognized by BioInformatics LLC with a 2018 Life Science Industry Award^® for best use of social media.

Dec 18, 2018

MilliporeSigma today announced it has extended and expanded its collaboration with Kuraray Europe to exclusively supply pharmaceutical polyvinyl alcohol (PVA) grades and improvements to benefit the pharmaceutical market.

Dec 10, 2018

MilliporeSigma, a leader in genome editing, today announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based biotechnology company genOway.